“Our organization has benefited across the pipeline from Venebio’s unique and visionary business model. Numerous times in years past, we have asked Venebio to leverage its growing global network of experts. With every new engagement, Venebio moves swiftly to put together a project-specific team, built around some of the world’s leading talent, whether in clinical trial design and analysis, personalized medicine, pharmacovigilance, pharmacoepidemiology or patent due diligence support, to provide consistently high-quality, on-time deliverables to our business.”
Christian Heidbreder, PhD, Global Head of R&D, Indivior, Inc.
“Venebio provided impressive and timely scientific leadership and regulatory guidance for a major initiative at MWV Healthcare. Venebio and its team of experts planned and spearheaded a remarkable research effort to establish the scientific evidence behind our regulatory approach. Their strategy culminated in the publication of two papers in a leading scientific journal, and a successful ongoing engagement with officials at the highest levels of the FDA regarding the exciting role of innovative pharmaceutical packaging in addressing the huge public health problems of medication non-adherence and medication errors. We are extremely pleased with our collaboration with such a creative and forward-thinking research organization.”
Elizabeth Whalley Buono, Esq., VP, Global Quality, External and Regulatory Affairs, WestRock, Inc.
“Over the course of our 18-month project, Venebio provided valuable consulting services to my clinical team in the areas of statistical analysis, data management, and database development. We have always been very satisfied with the work they have done, and are especially appreciative of their willingness to meet some very aggressive timelines.”
Paul J. Fudala, PhD, RPh, Global Clinical Development Director, Indivior, Inc.
“Venebio is first and foremost devoted to the integrity of science and our clients count on that. Through seamless management and thorough analytical oversight, Venebio has become a trusted leader in the life sciences consulting field.”
Samuel L. Tarry, Jr., LLM in Global Health Law, Partner, McGuireWoods LLP
“Our organization has benefited across the pipeline from Venebio’s unique and visionary business model. Numerous times in years past, we have asked Venebio to leverage its growing global network of experts. With every new engagement, Venebio moves swiftly to put together a project-specific team, built around some of the world’s leading talent, whether in clinical trial design and analysis, personalized medicine, pharmacovigiliance, pharmacoepidemiology or patent due diligence support, to provide consistently high-quality, on-time deliverables to our business.”
Christian Heidbreder, PhD, Global Head of R&D, Indivior, Inc.
“In 2009, my academic research group began a highly productive relationship with Venebio. This dynamic collaboration has led to three successful NIH grant proposals to study the pathobiology of non-alcoholic and alcoholic liver disease, and several scientific presentations and manuscripts. Venebio is also currently negotiating with our University the transfer of license to a conjointly discovered biomarker technology for personalized medicine. I look forward to the long-term continuation of this fruitful academic-biotech partnership.”
Arun Sanyal, MD, Chairman, Gastroenterology, Virginia Commonwealth University